Latest Breaking News On - லூபஸ் அடித்தளம் ஆஃப் அமெரிக்கா - Page 1 : comparemela.com

MedCity News FDA approval of AstraZeneca lupus drug sets up competition with GSK’s Benlysta An AstraZeneca lupus drug has been awarded FDA approval for treating the most common form of the autoimmune disorder. The regulatory decision gives AstraZeneca a product that can compete head-to-head with GlaxoSmithKline’s lupus drug, Benlysta. Shares0   Patients who suffer from the most common form of lupus have a new treatment option, an AstraZeneca drug that is now the first new therapy for the autoimmune disorder since a GlaxoSmithKline medicine cleared the regulatory bar a decade ago. FDA approval of the AstraZeneca drug, anifrolumab, covers adults with moderate to severe systemic lupus erythematosus who are also receiving standard treatment that includes anti-inflammatory and immunosuppressing medications. AstraZeneca will market its new drug under the name “Saphnelo.”

United statesLupus foundation of americaLupus foundationஒன்றுபட்டது மாநிலங்களில்லூபஸ் அடித்தளம் ஆஃப் அமெரிக்காலூபஸ் அடித்தளம்